European Union

EPO Patent Grant EP3366126B1: Transgenic Mice for Antibody Production

The European Patent Office has granted patent EP3366126B1 for transgenic mice engineered to express human lambda immunoglobulin light chain variable domains. This patent, effective March 18, 2026, relates to advancements in antibody production and biotechnology.

EPO Grants Mammalian Cell Culture Patent EP2837680B1

The European Patent Office (EPO) has granted patent EP2837680B1 concerning mammalian cell culture. The patent was granted on March 18, 2026, and lists Brian D. Follstad, Rebecca E. McCoy, and Arvia E. Morris as inventors. This grant signifies the formal recognition of intellectual property rights for the patented technology.

EPO Patent EP3265098B1: Modulating Mecp2 Expression Compositions

The European Patent Office has granted patent EP3265098B1 for compositions intended to modulate Mecp2 expression. This patent, effective March 18, 2026, covers specific inventions related to biotechnology and pharmaceutical applications.

EPO Patent: Synthesis of 1-Butanol from Carbon Dioxide by Engineered Bacteria

The European Patent Office has published a patent application (EP2026030726A1) detailing the synthesis of 1-butanol from carbon dioxide using engineered bacteria. The patent application was published on March 18, 2026, and lists designated states across Europe.

EPO Patent Grant EP3077503B1 for Chondrogenesis Composition

The European Patent Office (EPO) has granted patent EP3077503B1 for a composition and method for inducing chondrogenesis or tenogenesis in mesenchymal stem cells. The patent was published on March 18, 2026, and lists Sarah Yolande Kristel Broeckx and Jan Hilda Marie Jozef Spaas as inventors. This grant pertains to specific International Patent Classifications related to cell culture.

EPO Patent Granted: Recombinant Mopeia Virus Vaccine Platform

The European Patent Office has granted patent EP3365005B1 for a recombinant Mopeia virus and vaccine platform. This patent covers specific inventions related to vaccine development and was published on March 18, 2026.

Immunotherapy Patent Grant EP3465203B1

The European Patent Office (EPO) has published patent grant EP3465203B1 concerning methods of immunotherapy. The patent, listing Rajiv Khanna and Corey Smith as inventors, was published on March 18, 2026. This grant is part of the EPO's ongoing dissemination of intellectual property information.

EPO Patent Grant EP3386554B1 for Bacterial Cellulose Membranes

The European Patent Office has granted patent EP3386554B1 for methods of producing biosynthetic bacterial cellulose membranes. The patent lists inventors from Schwarz, Chaid, Kumar, Vijay, and Raghavan, Madhavan, and covers various International Patent Classifications related to medical materials and biotechnology.

EPO Patent Bulletin: Improved Bakery Composition

The European Patent Office published patent EP3481205C0 concerning an improved bakery composition on March 18, 2026. This patent relates to specific IPC classifications including A21D and C12N, and is designated for several European states.

EPO Patent Granted for Peptides and Their Use

The European Patent Office (EPO) has granted patent EP3439682B1 for hypersensitive response elicitor-derived peptides and their use. The patent is effective March 18, 2026, and covers specific peptide sequences and their applications.